Qingdao Kangyuan Pharmaceutical Co. Ltd.(QKP) was founded in August 18 of 2001. The predecessors are Qingdao Biochemistry resource development Co. Ltd. founded in 1992 and Qingdao Kangyuan biochemistry resource development Co. Ltd.. QKP is one subsidiary of Qingdao Jiulong Biopharmaceutical Co., Ltd.. The main products are HCG, HMG, UK, FSH, UTI, Chymotrypsin, Trypsin and Hyaluronidase, protamine sulfate and other research, production and sales for raw materials.
Kangyuan is a national high-tech enterprise, Qingdao key enterprise to be listed and it is also the honorary chairman of Qingdao Jiaozhou Bio-pharmaceutical association and the vice- chairman of Shanghai Bio-pharmaceutical association. Kangyuan is the first and the only enterprise in China who passed the FDA inspection, recognized as the only and most complete and the largest Bio-pharmaceutical enterprise from Urine to API in the world. Passed the Chinese new drug GMP certificate in 2015.
To coordinate the national specific project “Twice hit twice build ”, QKP started the first and second battle of “Right-Defending Action” in domestic market of urine collection. Urine collection range covered five provinces, such as ShanDong, HeBei, JiangSu, AnHui and almost one hundred counties and cities. We have more than 20 thousands urine collection officers, urine suppliers more than one million.
HCG API had passed the FDA inspection in Jan 2013 , and this makes us to be the first company who passed the FDA inspection in China; We had successfully passed the FDA recertification in April 2016.
The technology of HCG, HMG and other products is leading to the international advanced level and be added in the “National Torch Plan project” by Chinese government. Kangyuan won the Ministry of science and technology development of private scientific and technological contribution award, scientific and technological progress second prize of Qingdao. 100 patents applications of company have been accepted by State Intellectual Property Office, 21 of them have been authorized.